Table 1.
Protective efficacies of heterologous prime and boost regimens using AdHu5 and AAV1 vaccines against sporozoite challengea.
| Prime | Boost | Protected/challenged (% protective efficacyb) |
|---|---|---|
| EXPERIMENT 1 | ||
| PBS | PBS | 2/10 (0) |
| AAV1-G(–) | AAV1-G(–) | 2/10 (0) |
| AAV1-G(–) | AdHu5 | 2/10 (0) |
| AdHu5 | AAV1-G(–) | 5/10 (37.5) |
| AdHu5 | AdHu5 | 3/10 (12.5) |
| EXPERIMENT 2 | ||
| PBS | PBS | 0/10 (0) |
| AdHu5 | AAV1-G(–) | 2/10 (20) |
| AdHu5 | AAV1-G(+) | 8/10 (80)c |
a
AdHu5-PfCSP, AAV1-PfCSP-G(–), and AAV1-PfCSP-G(+) are shown as AdHu5, AAV1-G(–), and AAV1-G(+), respectively. Immunized mice were intravenously challenged with 1,000 (Exp. 1) or 500 (Exp. 2) PfCSP-Tc/Pb sporozoites and checked for blood-stage infections by microscopic examination of Giemsa-stained thin smears of tail blood. Protection was defined as the complete absence of blood-stage parasitemia on day 14 post-challenge.
b
Protective efficacy was calculated as described in the Materials and Methods.
c
Significant difference with the PBS group as determined using a Fisher's exact probability test (p < 0.001).